Metformin inhibits small intestinal neuroendocrine tumor growth in vivo - Takeaways - MDSpire

Metformin inhibits small intestinal neuroendocrine tumor growth in vivo

  • By

  • Fredrik Axling

  • Samuel Backman

  • Per Hellman

  • Olov Norlén

  • Elham Barazeghi

  • Peter Stålberg

  • June 25, 2026

  • 0 min

Share

  • 1

    Small intestinal neuroendocrine tumors (SI-NETs) are the most common tumors of the small intestine and often present with metastases at diagnosis.

  • 2

    Metformin, a diabetes medication, has shown anticancer activity in preclinical studies, including those involving SI-NETs.

  • 3

    The study investigated the effects of metformin on SI-NET cell growth in vivo and analyzed miRNA expression profiles in treated cells.

  • 4

    Animal experiments were conducted using NMRI-nude mice, with tumor xenografts established from SI-NET cell lines.

  • 5

    Tumor growth was monitored, and the study aimed to elucidate the mechanisms of metformin's anti-proliferative effects on SI-NETs.

Original Source(s)

Metformin inhibits small intestinal neuroendocrine tumor growth in vivo

  • by Fredrik Axling, Samuel Backman, Per Hellman, Olov Norlén, Elham Barazeghi, Peter Stålberg

  • June 25, 2026

Related Content

Prevalence of depression in patients with advanced cancer receiving palliative care: a meta-analysis of self‐report instruments

Distribution analysis of gynecological carcinomas with concurrent second primary carcinomas

The mechanism of action, clinical significance, and research progress of tumor antigen-specific T cells in the treatment of HCC